US20130226063A1 - Buffered adhesive compositions for skin-adhering products and methods of making same - Google Patents

Buffered adhesive compositions for skin-adhering products and methods of making same Download PDF

Info

Publication number
US20130226063A1
US20130226063A1 US13/778,497 US201313778497A US2013226063A1 US 20130226063 A1 US20130226063 A1 US 20130226063A1 US 201313778497 A US201313778497 A US 201313778497A US 2013226063 A1 US2013226063 A1 US 2013226063A1
Authority
US
United States
Prior art keywords
molecular weight
high molecular
acrylic acid
acid
weight polymeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/778,497
Inventor
Michael Gerard Taylor
Richard Iwao Murahata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hollister Inc
Original Assignee
Hollister Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hollister Inc filed Critical Hollister Inc
Priority to US13/778,497 priority Critical patent/US20130226063A1/en
Assigned to HOLLISTER INCORPORATED reassignment HOLLISTER INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MURAHATA, RICHARD IWAO, TAYLOR, MICHAEL GERARD
Publication of US20130226063A1 publication Critical patent/US20130226063A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/02Adhesive plasters or dressings
    • A61F13/0246Adhesive plasters or dressings characterised by the skin adhering layer
    • A61F13/0253Adhesive plasters or dressings characterised by the skin adhering layer characterized by the adhesive material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/02Adhesive plasters or dressings
    • A61F13/0203Adhesive plasters or dressings having a fluid handling member
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/44Devices worn by the patient for reception of urine, faeces, catamenial or other discharge; Portable urination aids; Colostomy devices
    • A61F5/443Devices worn by the patient for reception of urine, faeces, catamenial or other discharge; Portable urination aids; Colostomy devices having adhesive seals for securing to the body, e.g. of hydrocolloid type, e.g. gels, starches, karaya gums
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/58Adhesives
    • A61L15/585Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/60Liquid-swellable gel-forming materials, e.g. super-absorbents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0031Hydrogels or hydrocolloids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/043Mixtures of macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061Use of materials characterised by their function or physical properties
    • A61L26/008Hydrogels or hydrocolloids
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09JADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J123/00Adhesives based on homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Adhesives based on derivatives of such polymers
    • C09J123/02Adhesives based on homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Adhesives based on derivatives of such polymers not modified by chemical after-treatment
    • C09J123/18Homopolymers or copolymers of hydrocarbons having four or more carbon atoms
    • C09J123/20Homopolymers or copolymers of hydrocarbons having four or more carbon atoms having four to nine carbon atoms
    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09JADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
    • C09J133/00Adhesives based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Adhesives based on derivatives of such polymers
    • C09J133/02Homopolymers or copolymers of acids; Metal or ammonium salts thereof

Definitions

  • This disclosure relates to the technical field of adhesive compositions for medical dressings and skin-adhering devices such as ostomy products, wound dressings, and other medical products intended to be adhesively secured to skin surfaces of users.
  • the disclosure is specifically concerned with such adhesive compositions that contain a high molecular weight buffer and are capable of absorbing fluids and maintaining normal skin pH levels and to methods for making the compositions.
  • a product is adhered directly to the skin, such as in the case of a wound dressing or an ostomy skin barrier.
  • a product must be securely affixed to the skin to keep it in place and must absorb whatever fluid is produced under or near it, such as perspiration, wound exudate, fluid fecal matter, and the like.
  • Wound dressings typically perform several functions to facilitate healing. These functions include absorbing wound exudate, regulating pH to create an optimal healing environment and reduce microbial activity, and protecting the wound from infection. Many such wound dressings are self-adhesive and contain an adhesive layer that typically adheres to the peri-wound skin of a wearer. It is known that skin often becomes irritated under wound dressings.
  • known wound dressings achieve the aforementioned functionality through the use of several individual components.
  • known dressings often use hydrocolloids, e.g., carboxymethylcellulose (CMC), pectin, or gelatin, to absorb wound exudate.
  • CMC carboxymethylcellulose
  • pectin e.g., pectin
  • gelatin e.g., gelatin
  • hydrocolloids e.g., carboxymethylcellulose (CMC), pectin, or gelatin
  • CMC carboxymethylcellulose
  • pectin e.g., pectin, or gelatin
  • compositions containing hydrocolloids such as those described above require multiple steps, due to the temperature-sensitivity of these materials. It would be preferred to minimize the number of preparative steps (ideally to just one) and the number of separate ingredients.
  • Adhesive compositions containing hydrocolloids are well known, as disclosed, for example, in U.S. Pat. Nos. 5,571,080, 3,339,546, 4,192,785, 4,296,745, 4,367,732, 4,813,942, 4,231,369, 4,551,490, 4,296,745, 4,793,337, 4,738,257, 4,867,748, 5,059,169, and 7,767,291, the disclosures of which are incorporated herein by reference.
  • Hydrocolloids are commonly used in what is commonly referred to as hydrocolloid skin barriers or hydrocolloid wound dressings. Such skin barriers and wound dressings normally include a water-insoluble pressure-sensitive adhesive as a continuous phase with particles of one or more hydrocolloids dispersed throughout the adhesive as a liquid-absorbing and swellable discontinuous phase.
  • the water-insoluble adhesive phase of commercial skin barriers and wound dressings typically consists of polyisobutylene (PIB), or block copolymers such as styrene-isoprene-styrene (SIS), or blends of these materials.
  • PIB polyisobutylene
  • SIS block copolymers
  • the surface tack may be modified by the addition of tackifier components.
  • a pouch to contain the expelled fecal material or urine.
  • the pouch is normally attached to the peristomal skin with an adhesive skin barrier that attaches the pouch to the skin.
  • a skin barrier is normally replaced every three to five days but may remain in place for up to a week.
  • the peristomal skin may become irritated due to prolonged contact with the fecal material. Over time, the irritation can become severe.
  • an ostomy skin barrier has an adhesive tape border around its periphery for additional security.
  • the adhesive for said border is typically an acrylic adhesive.
  • skin barrier is intended to include any skin barrier either with or without an adhesive tape border.
  • Both wound exudate and fecal material contain proteolytic and lipolytic enzymes. These enzymes, when contained in a closed, moist environment, are thought to degrade the stratum corneum and contribute to the observed irritation. Moreover, since both wound dressings and ostomy skin barriers are normally removed and re-applied on a regular basis, the integrity of the skin under them becomes compromised and more susceptible to irritation than normal skin.
  • Normal skin has a so-called “acid mantle” which maintains the surface of the skin at a pH typically between about 4.0 and 5.5 (slightly acidic). This pH range promotes the growth of beneficial microorganisms and retards the growth of harmful microorganisms, while helping to maintain the integrity of the skin. At this pH level, the activity of (and hence the damage caused by) the proteolytic and lipolytic enzymes from wound exudate or fecal matter would not be severe. However, the wound exudate and stomal fluid normally have a pH in the range of 6.0 to 8.0. This increase in pH causes a significant increase in the activity of the enzymes and hence in their ability to cause irritation.
  • an adhesive composition containing a suitable buffer to maintain the pH of the skin under a wound dressing or a stomal skin barrier or the like product at about 4.0 to about 5.5 without being inherently irritating to the user's skin. It would also be desirable to have such a composition that could be manufactured in a minimal number of steps and using a minimal number of ingredients.
  • a high molecular weight polymeric buffering adhesive is provided that is capable of fluid absorption and pH buffering.
  • a method for preparing the high molecular weight polymeric buffering adhesive.
  • a wound dressing in accordance with another aspect of the disclosure, includes a high molecular weight polymeric buffer capable of fluid absorption and pH buffering.
  • an ostomy skin barrier includes a high molecular weight polymeric buffer capable of fluid absorption and pH buffering.
  • a method for using the high molecular weight polymeric buffer to manufacture a skin-adhering device such as a skin-adhering medical device.
  • An embodiment of the disclosure is a wound dressing that includes a flexible outer layer and a high molecular weight polymeric buffering adhesive applied to one side thereof, said adhesive providing pH buffering and fluid absorption with minimal irritation to a wearer's skin.
  • an ostomy skin barrier that includes a high molecular weight polymeric buffering adhesive applied to one side thereof, said adhesive composition providing pH buffering and fluid absorption with minimal irritation to a wearer's skin.
  • One embodiment of the present disclosure is directed to an adhesive composition
  • a high molecular weight buffer that absorbs fluids such as perspiration, wound exudate, and fecal matter, adjusts pH, and reduces enzymatic activity.
  • an embodiment of the present disclosure contemplates use of high molecular weight polymers that are rich in acidic sites.
  • Polymers with polyacid functionality can serve as buffers through the use of mixtures of their protonated and neutralized forms. Indeed, the abundance of acidic sites enables a single polymer to be partially neutralized so that each polymer chain has both acidic and basic sites, thereby forming an effective buffer from a single polymer species.
  • Any high molecular weight polymer having pendant carboxyl groups that are capable of being partially neutralized is suitable for use in the present disclosure.
  • Suitable polymers include, for example, polyacrylic acid and poly(2-alkyl acrylic acid) in which the alkyl chain is from one to five carbons in length and may be straight chain or branched chain.
  • Poly methacrylic acid is the preferred poly (2-alkyl acrylic acid).
  • suitable polymers are copolymers of any of acrylic acid and 2-alkyl acrylic acid monomers, copolymers of the foregoing monomers with maleic acid, olefinic polymers substituted with side chains containing free carboxylic acid groups, such as polyvinyl alcohol esterified with a diacid, triacid or polyacid (e.g., polyvinyl alcohol succinate), and the like.
  • the buffering adhesive composition of the disclosure can employ any high molecular weight polymer having partially neutralizable pendant carboxyl groups that is capable of maintaining the pH of a test product at less than about 6.0 in the phosphate buffer challenge test described in Example 1.
  • Polymers particularly well suited for use in an embodiment of the disclosure include polyacrylic acid (PAA) and polymethacrylic acid (PMA). Both PAA and PMA are available from, for example, Sigma-Aldrich Co., in a variety of forms, e.g., powder and solution, and in a range of molecular weights. Of the acrylic acid derivatives, PAA is preferred because it has the highest density of carboxylic acid sites per gram of compound and hence the highest extent of buffering per gram of compound. As used herein, “high molecular weight” PAA means greater than about 60,000 Daltons and as high as several million Daltons. The term has similar meanings for PMA and the other polymers described above.
  • these poly-acidic polymers can be partially neutralized to provide both the acid and salt components of the buffer system on the same molecule.
  • Typical extents of neutralization are from about 20% to about 40%, preferably from about 25% to about 37% for PAA and similar values for other polymers. These ranges include all values within the end points, and particularly 28%, 31%, 34%, and 36%.
  • Partial neutralization of PAA may be achieved by mixing PAA (plus water if appropriate) with a stoichiometrically appropriate amount of a strong base (e.g., NaOH) until the desired degree of neutralization is achieved.
  • a strong base e.g., NaOH
  • Other polymers may be treated similarly.
  • Partially neutralized polyacids such as PAA are also available commercially.
  • PAA and related polymers exist in both cross-linked and non cross-linked forms and the degree of cross-linking can be varied.
  • Cross-linked PAA is known to be an excellent absorbent.
  • the polymers used in the present disclosure are preferably not cross-linked.
  • the inventors have discovered that cross-linked PAA (for example) may be excessively absorbent, and its use in the present disclosure would lead to excessive swelling and possible rupture of the product in which it is being used.
  • non cross-linked PAA and related polymers are preferred because of their ability to form mucoadhesives to aid in the retention on the skin of the device with which the adhesive composition of the disclosure is used.
  • high molecular weight polymers e.g., PAA and PMA
  • PAA and PMA both provide effective pH buffering and absorb fluids such as perspiration, wound exudate, or fecal matter.
  • the polymers function similarly to hydrocolloids such as pectin and CMC when dispersed within an adhesive matrix. That is, they absorb and swell and form viscous solutions that provide mucoadhesion against a wearer's skin.
  • the high molecular weight polymers may be the sole hydrocolloid component or in other embodiments, they may be combined with other hydrocolloids, depending on the application and desired fluid handling capabilities of the wound dressing or skin barrier.
  • high molecular weight PAA is combined with polyisobutylene and either styrene-isoprene-styrene copolymer or polymer fibers (or both) for increased strength.
  • the adhesive composition comprises high molecular weight PAA, polyisobutylene, and styrene-isoprene copolymer.
  • the adhesive composition comprises high molecular weight PAA, polyisobutylene, styrene-isoprene copolymer and fibers such as cotton or preferably polyolefin such as polyethylene or polypropylene.
  • the adhesive component of the compositions of this disclosure may be any material that has pressure-sensitive adhesive properties with a strong affinity for the material of the fibers. It may be a single pressure-sensitive adhesive or a combination of two or more pressure-sensitive adhesives.
  • Adhesives useful in the present disclosure include, for example, those based on natural rubbers, synthetic rubbers, styrene block copolymers, polyvinyl ethers, poly(meth)acrylates (including both acrylates and methacrylates), polyolefins and silicones.
  • a particular adhesive believed to be a preferred material of choice for this disclosure is a polyolefin, namely, polyisobutylene (PIB), but other pressure-sensitive adhesive materials having similar properties are believed suitable.
  • the fibers in the adhesive composition may be any fibrous material known in the art but preferably are compatible with, and even have a strong affinity for, the tacky adhesive component. It has been found that polyolefins such as polyethylene and polypropylene are highly compatible with PIB and are easily wetted by that adhesive medium. Both are non-polar saturated hydrocarbons.
  • a high molecular weight polymeric buffering adhesive such as PAA or PMA and a pressure-sensitive adhesive such as PIB are combined in a single mixing step.
  • Other materials such as SIS and/or polypropylene fibers may additionally be combined in the single mixing step.
  • This manufacturing embodiment has the benefit of avoiding multiple mixing steps, thereby saving time and minimizing equipment use.
  • a preferred embodiment in this manufacture is the combination of the desired amounts of PAA, PIB, and SIS in a single mixing step.
  • such PIB is present as relatively high molecular weight PIB (molecular weight in the range of about 40,000 to 60,000).
  • a skin barrier for ostomy use would normally contain 60,000 molecular weight PIB in the range of 50 wt. % to 65 wt. % or 40,000 molecular weight PIB in the range of 40 wt. % to about 55 wt. %.
  • combinations of 40,000 molecular weight and 60,000 molecular weight PIB may also be used, such as 32.5 wt. % 40,000 molecular weight PIB and 32.5 wt. % 60,000 molecular weight PIB.
  • the partially neutralized high molecular weight polyacid comprises from about 20 wt. % to about 45 wt. % of the adhesive composition.
  • the PIB component may comprise from about 40 wt. % to about 65 wt. % of the adhesive composition.
  • the SIS component may comprise from about 0 wt. % to about 25 wt. % of the adhesive composition.
  • the adhesive composition comprises from about 20 wt. % to about 45 wt. % partially neutralized polyacrylic acid, from about 40 wt. % to about 55 wt. % PIB, and from about 5 wt. % to about 15 wt. % SIS.
  • One preferred adhesive composition comprises about 45 wt. % partially neutralized PAA, about 40 wt. % PIB, and about 15 wt. % SIS.
  • Another preferred adhesive composition comprises about 30 wt. % partially neutralized PAA, about 55 wt. % PIB, and about 15 wt. % SIS.
  • Another preferred adhesive composition comprises about 54 wt. % PIB, about 6 wt. % polyethylene fibers, and about 40 wt. % 25% neutralized high molecular weight PAA.
  • Still another preferred adhesive composition comprises about 51 wt. % PIB, about 20 wt. % SIS, about 2 wt. % polyethylene fibers, and about 27 wt. % 35% neutralized high molecular weight PAA.
  • the PIB is preferably Nippon Himol 4H as described below.
  • the buffering adhesive composition of the disclosure it is highly desirable that the composition be at least minimally absorptive.
  • the buffering capability of the present compositions is related in part to their absorptive capability. If no absorption were to occur, the high molecular weight polymeric buffer would not be contacted by the wound exudate or fecal material and hence would not be effective.
  • compositions having lower absorptive capacity are included within the present disclosure, the compositions of the disclosure should preferable have an absorptive capacity of at least about 0.15 g/cm 2 as measured in the test of Example 1.
  • the buffering capability of compositions having lower absorptive capacity is less optimal.
  • Test samples were prepared by heat compression of barrier materials to a thickness of 0.020 inches and were laminated between a removable release liner and a flexible backing film.
  • Polyacrylic acid in water was neutralized to the desired degree by addition of aqueous sodium hydroxide.
  • the resulting solution of partially neutralized polyacrylic acid was dried in aluminum trays at 150° C. for approximately 20 hours. The dried material was crushed and then ground in a hammer mill (Model JT, Homiloid Machine, Fitzpatrick Corporation). Laser light scattering particle size analysis of different batches showed mean particle sizes in the range from 70 to 150 microns.
  • partially neutralized Polyacrylic Acid was obtained pre-neutralized in dry powder form: Aronvis AH-106X (35% neutralized Polyacrylic acid) produced by Toa Gosei.
  • Fluid absorption was measured following the practice of standard EN 13726-1:2002 (Test methods for primary wound dressings—Part 1: Aspects of absorbency, Section 3.3).
  • the hydrating fluid was normal saline (0.9% NaCl in water).
  • the mass of fluid absorbed was measured by the weight gain in samples of 10 cm 2 surface area exposed to 20 mL normal saline. Samples were maintained in an oven (37° C., 15% relative humidity) for fixed time periods. Surface pH measurements were performed on samples following fluid absorption using a calibrated pH meter and a flat pH probe (Ross® model 8135BN).
  • a stock buffer solution (100 mM in Phosphate, 0.9% NaCl, pH 7.4) was prepared. Lower phosphate concentration buffers were prepared by dilution of the stock buffer with appropriate volumes of 0.9% NaCl. A 10 cm 2 surface of the barrier was exposed to 10 mL of buffer challenge solution.
  • compositions were prepared using a Brabender Type REE6 mixer at 85° C.
  • the required amounts of polyethylene fibers and partially neutralized polyacrylic acid were pre-blended.
  • the required weight of PIB was added to the mixer and was mixed at 36 rpm for 2 minutes.
  • the pre-blended fibers and powder were added over the course of 3 minutes while mixing at 36 rpm.
  • the mixing chamber was sealed and vacuum was applied and mixing was continued for 15 minutes. Vacuum was released and the mixtures were removed from the mixer and allowed to equilibrate at room conditions before any testing was undertaken.
  • Table 1 below shows compositions prepared in this fashion with weight percentages of the indicated ingredients along with testing results for these compositions.
  • Table 1 and Table 2 below the 6 Hour and 24 Hour Buffer Challenges used a 100 mM phosphate buffer at pH 7.4 in 0.9% NaCl solution.
  • a second series of formulations based on PIB (two different molecular weights), Styrene-Isoprene-Styrene copolymer and partially neutralized polyacrylic acid (25% neutralized Noverite K-702) were prepared.
  • compositions were prepared using a Brabender Type REE6 mixer at 140° C.
  • the required weight of SIS was added to the mixer and was mixed at 36 rpm for 7 minutes.
  • the required amount of PIB and mixing was continued at 36 rpm.
  • the mixer speed was increased to 100 rpm and mixing was continued for another 11 minutes.
  • the required amount of partially neutralized polyacrylic acid (25% degree of neutralization) was added and mixing was continued for 4 minutes.
  • the mixing chamber was sealed and vacuum was applied and mixing was continued for 16 minutes. Vacuum was released and the mixtures were removed from the mixer and allowed to equilibrate at room conditions before any testing was undertaken. Tests were performed as in Example 1.
  • Table 2 shows compositions prepared in this fashion with weight percentages of the indicated ingredients along with testing results for these compositions.
  • a third series of formulations based on PIB, Styrene-Isoprene-Styrene copolymer, polyethylene fibers and partially neutralized polyacrylic acid (35% Aronvis AH-106X) were prepared.
  • a masterbatch composed of 50% PIB (Nippon 4H) and 50% Styrene-Isoprene-Styrene copolymer was prepared using a Brabender Type REE6 mixer at 140° C. The required weight of SIS was added to the mixer and was mixed at 36 rpm for 7 minutes. The required amount of PIB was added as mixing was continued at 36 rpm. The mixer speed was then increased to 100 rpm and mixing was continued for another 11 minutes. The masterbatch was removed from the mixer and cooled to room temperature before further use.
  • compositions were prepared using a Brabender Type REE6 mixer at 85° C.
  • the required amounts of polyethylene fibers and partially neutralized polyacrylic acid were pre-blended.
  • the required amount of 50:50 masterbatch prepared as described above was added to the mixer and was mixed at 36 rpm for 4 minutes.
  • the required amount of additional PIB was added to the mixer and was mixed at 36 rpm for 4 minutes.
  • the pre-blended fibers and powder were then added over the course of 3 minutes while mixing at 36 rpm.
  • Mixing continued for a further 2 minutes, following which the mixing chamber was sealed and vacuum was applied while mixing was continued for 12 minutes. Vacuum was released and the mixture was removed from the mixer and allowed to equilibrate at room conditions before any testing was undertaken. Tests were performed as in Example 1.
  • Table 3 shows compositions prepared in this fashion with weight percentages of the indicated ingredients along with testing results for these compositions.
  • a formulation based on PIB, Styrene-Isoprene-Styrene copolymer, Polypropylene fibers and partially neutralized polyacrylic acid (35% neutralized Aronvis AH-106X) was prepared in a single step mixing process.
  • the composition was prepared using a Brabender Type REE6 mixer at 140° C.
  • the required weight of SIS was added to the mixer and was mixed at 36 rpm for 7 minutes.
  • the required amount of PIB and mixing was continued at 36 rpm.
  • the mixer speed was increased to 100 rpm and mixing was continued for another 11 minutes.
  • the required amounts of partially neutralized polyacrylic acid and Polypropylene fibers were pre-blended and the blend was added and mixing was continued for 4 minutes.
  • the mixing chamber was sealed and vacuum was applied and mixing was continued for 16 minutes. Vacuum was released and the mixtures were removed from the mixer and allowed to equilibrate at room conditions before any testing was undertaken. Testing was done as in Example 1 and results are shown in Table 4 below.
  • High molecular weight polymers such as those set forth above provide both enhanced pH buffering capacity and absorption with reduced skin irritation.
  • low molecular weight acids such as citric acid
  • low molecular weight acid buffer systems cause unacceptable irritation to the user's skin for use as contemplated herein.
  • a buffering adhesive compositions similar to those of the disclosure but using a citric acid/citrate buffer instead of a high molecular weight polymer buffer was used in an adhesive dressing on human subjects, the subjects developed punctate ulcers under the dressing. The test results are shown below. Such an adhesive composition would be unsuitable for medical use. This result was both surprising and unexpected.
  • the evaluation of a citric acid buffering system is described in Example 6 below.
  • barrier materials are self-adhesive, it was possible to partially differentiate between the contribution from irritation due to mechanical properties (skin stripping) and chemical irritation, by comparing irritation resulting from direct application with that observed when the barrier was isolated from the skin using a non-woven pad moistened with sterile normal saline as well as using barriers constructed with and without buffering material.
  • the irritation potential of the formulation containing 20% citrate barrier was similar to that of the positive control (mean rank 9.27).
  • the barrier formulation containing citrate caused irritation accompanied by focal erosions (punctate lesions), which was different from the more uniform irritation typically observed with exposure to SLS.
  • the barrier formulated with PAA was significantly less irritating that either the positive control or the citrate buffer formulation.
  • the slight irritation observed due to repeated exposure to the PAA barrier formulation was more uniform ‘glazing’ characteristic of repeated mechanical trauma, i.e., tape stripping. Both of these groups were different from the negative control (mean rank 2.68).
  • PAA buffer applied in petrolatum 31.8% PAA in petrolatum was non-irritating, indicating a lack of inherent chemical irritation due to repeated exposure to PAA. This observation is consistent with the interpretation that the minor irritation observed with the barrier formulated with PAA is due to repeated mechanical damage.
  • An embodiment of the present disclosure contemplates the use of a high molecular weight polymeric buffer incorporated into the adhesive layer of a wound dressing.
  • the wound dressing preferably includes a flexible outer layer such as a film.
  • a hydrocolloid layer is on an inner side of the outer layer and contains the inventive high molecular weight polymeric buffer along with, optionally, an additional hydrocolloid such as CMC or pectin.
  • the hydrocolloid layer is in direct contact with the wound bed.
  • the wound dressing includes an adhesive component having a very high cohesive strength when hydrated to avoid potential disintegration of the dressing components in the wound bed.
  • an adhesive component having a very high cohesive strength when hydrated to avoid potential disintegration of the dressing components in the wound bed.
  • non-adhesive wound dressings incorporating the inventive buffer may also be possible.
  • a formulation suitable for a self-adhesive wound dressing would be, for example, formulation 7 in Table 2 (40% PIB, 15% SIS, 45% PAA) which has high cohesive strength due to the relatively high SIS content along with high fluid absorption and buffering properties, useful for managing wound exudate.
  • formulation 7 in Table 2 40% PIB, 15% SIS, 45% PAA
  • Those of ordinary skill in the art would know how to use this formulation in preparation of a self-adhesive wound dressing.
  • Another embodiment of the present disclosure contemplates the use of a high molecular weight buffer incorporated into an ostomy skin barrier.
  • the skin barrier may be permanently attached to an ostomy pouch (a “one step” or one piece arrangement) or may be separately attached using a flange clip system (a two piece arrangement).
  • This embodiment of the disclosure will maintain the pH of the peristomal skin closer to the normal skin pH range of about 4.0 to about 5.5, thus reducing or eliminating the occurrence of irritation in the peristomal area.
  • Useful example formulations for ostomy skin barriers include those containing either polyethylene fibers or SIS.
  • formulation 3 of Table 1 combines desirable fluid handling ability with excellent pH control.
  • Formulation 1 in Table 2 is an example of a formulation incorporating SIS with similar fluid handling and pH control. Those of ordinary skill in the art would know how to use this formulation in preparation of an ostomy skin barrier.
  • compositions of the disclosure are described above.
  • the compositions may be used to manufacture any skin-adhering device by applying to a side or surface of the device an amount of the composition effective to securely attach the device to the skin of the intended user.

Abstract

Provided are buffered adhesive compositions comprising a high molecular weight polymeric buffer and products such as wound dressings and ostomy skin barriers incorporating the compositions.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority from U.S. provisional applications 61/604,663, filed Feb. 29, 2012, and 61/668,178, filed Jul. 5, 2012, each of which is incorporated herein by reference in its entirety.
  • FIELD OF THE DISCLOSURE
  • This disclosure relates to the technical field of adhesive compositions for medical dressings and skin-adhering devices such as ostomy products, wound dressings, and other medical products intended to be adhesively secured to skin surfaces of users. The disclosure is specifically concerned with such adhesive compositions that contain a high molecular weight buffer and are capable of absorbing fluids and maintaining normal skin pH levels and to methods for making the compositions.
  • BACKGROUND
  • In a number of medical uses, a product is adhered directly to the skin, such as in the case of a wound dressing or an ostomy skin barrier. Such a product must be securely affixed to the skin to keep it in place and must absorb whatever fluid is produced under or near it, such as perspiration, wound exudate, fluid fecal matter, and the like.
  • Wound dressings typically perform several functions to facilitate healing. These functions include absorbing wound exudate, regulating pH to create an optimal healing environment and reduce microbial activity, and protecting the wound from infection. Many such wound dressings are self-adhesive and contain an adhesive layer that typically adheres to the peri-wound skin of a wearer. It is known that skin often becomes irritated under wound dressings.
  • Known wound dressings achieve the aforementioned functionality through the use of several individual components. For example, known dressings often use hydrocolloids, e.g., carboxymethylcellulose (CMC), pectin, or gelatin, to absorb wound exudate. While some hydrocolloids are also capable of independently adjusting pH, the degree of pH buffering they can provide is limited by the amount of available hydrocolloid in the dressing, which, in turn, is dependent on the desired fluid handling properties of the dressing. Moreover, the buffering effect of hydrocolloids alone is not optimal.
  • Moreover, the manufacture of adhesive compositions containing hydrocolloids such as those described above requires multiple steps, due to the temperature-sensitivity of these materials. It would be preferred to minimize the number of preparative steps (ideally to just one) and the number of separate ingredients.
  • Adhesive compositions containing hydrocolloids are well known, as disclosed, for example, in U.S. Pat. Nos. 5,571,080, 3,339,546, 4,192,785, 4,296,745, 4,367,732, 4,813,942, 4,231,369, 4,551,490, 4,296,745, 4,793,337, 4,738,257, 4,867,748, 5,059,169, and 7,767,291, the disclosures of which are incorporated herein by reference. Hydrocolloids are commonly used in what is commonly referred to as hydrocolloid skin barriers or hydrocolloid wound dressings. Such skin barriers and wound dressings normally include a water-insoluble pressure-sensitive adhesive as a continuous phase with particles of one or more hydrocolloids dispersed throughout the adhesive as a liquid-absorbing and swellable discontinuous phase.
  • The water-insoluble adhesive phase of commercial skin barriers and wound dressings typically consists of polyisobutylene (PIB), or block copolymers such as styrene-isoprene-styrene (SIS), or blends of these materials. The surface tack may be modified by the addition of tackifier components.
  • Patients with a permanent or temporary ostomy (colostomy, ileostomy, and the like) have need of a pouch to contain the expelled fecal material or urine. The pouch is normally attached to the peristomal skin with an adhesive skin barrier that attaches the pouch to the skin. A skin barrier is normally replaced every three to five days but may remain in place for up to a week. During use of the barrier, the peristomal skin may become irritated due to prolonged contact with the fecal material. Over time, the irritation can become severe.
  • In some applications, an ostomy skin barrier has an adhesive tape border around its periphery for additional security. The adhesive for said border is typically an acrylic adhesive. As used herein, the term “skin barrier” is intended to include any skin barrier either with or without an adhesive tape border.
  • Both wound exudate and fecal material contain proteolytic and lipolytic enzymes. These enzymes, when contained in a closed, moist environment, are thought to degrade the stratum corneum and contribute to the observed irritation. Moreover, since both wound dressings and ostomy skin barriers are normally removed and re-applied on a regular basis, the integrity of the skin under them becomes compromised and more susceptible to irritation than normal skin.
  • Normal skin has a so-called “acid mantle” which maintains the surface of the skin at a pH typically between about 4.0 and 5.5 (slightly acidic). This pH range promotes the growth of beneficial microorganisms and retards the growth of harmful microorganisms, while helping to maintain the integrity of the skin. At this pH level, the activity of (and hence the damage caused by) the proteolytic and lipolytic enzymes from wound exudate or fecal matter would not be severe. However, the wound exudate and stomal fluid normally have a pH in the range of 6.0 to 8.0. This increase in pH causes a significant increase in the activity of the enzymes and hence in their ability to cause irritation.
  • Current skin barriers incorporating hydrocolloids such as pectin and CMC do have limited pH buffering capacity. When exposed to water or saline solution, they are capable of adjusting pH to a level in the desired range from about 4.0 to 5.5. However, it is important to note that physiological fluids such as stoma output or wound exudates are buffered, typically at pH levels close to neutral. When current skin barriers are exposed to such fluids, the buffering capacity inherent in the physiological fluid overwhelms the weak buffering capacity of the skin barrier. As a result, the pH at the surface of the skin barrier increases to approach the pH of the fluid used to challenge the skin barrier. Thus, it is desirable to provide a skin barrier with enhanced pH buffering capacity.
  • In view of the above, it would be desirable to have an adhesive composition containing a suitable buffer to maintain the pH of the skin under a wound dressing or a stomal skin barrier or the like product at about 4.0 to about 5.5 without being inherently irritating to the user's skin. It would also be desirable to have such a composition that could be manufactured in a minimal number of steps and using a minimal number of ingredients.
  • SUMMARY
  • In accordance with one aspect of the disclosure, a high molecular weight polymeric buffering adhesive is provided that is capable of fluid absorption and pH buffering.
  • In accordance with another aspect of the disclosure, a method is provided for preparing the high molecular weight polymeric buffering adhesive.
  • In accordance with another aspect of the disclosure, a wound dressing is provided that includes a high molecular weight polymeric buffer capable of fluid absorption and pH buffering.
  • In accordance with another aspect of the disclosure, an ostomy skin barrier is provided that includes a high molecular weight polymeric buffer capable of fluid absorption and pH buffering.
  • In accordance with another aspect of the disclosure, a method is provided for using the high molecular weight polymeric buffer to manufacture a skin-adhering device such as a skin-adhering medical device.
  • An embodiment of the disclosure is a wound dressing that includes a flexible outer layer and a high molecular weight polymeric buffering adhesive applied to one side thereof, said adhesive providing pH buffering and fluid absorption with minimal irritation to a wearer's skin.
  • Another embodiment of the disclosure is an ostomy skin barrier that includes a high molecular weight polymeric buffering adhesive applied to one side thereof, said adhesive composition providing pH buffering and fluid absorption with minimal irritation to a wearer's skin.
  • DESCRIPTION OF A PREFERRED EMBODIMENT
  • One embodiment of the present disclosure is directed to an adhesive composition comprising a high molecular weight buffer that absorbs fluids such as perspiration, wound exudate, and fecal matter, adjusts pH, and reduces enzymatic activity.
  • In particular, an embodiment of the present disclosure contemplates use of high molecular weight polymers that are rich in acidic sites. Polymers with polyacid functionality can serve as buffers through the use of mixtures of their protonated and neutralized forms. Indeed, the abundance of acidic sites enables a single polymer to be partially neutralized so that each polymer chain has both acidic and basic sites, thereby forming an effective buffer from a single polymer species. Any high molecular weight polymer having pendant carboxyl groups that are capable of being partially neutralized is suitable for use in the present disclosure. Suitable polymers include, for example, polyacrylic acid and poly(2-alkyl acrylic acid) in which the alkyl chain is from one to five carbons in length and may be straight chain or branched chain. Poly methacrylic acid is the preferred poly (2-alkyl acrylic acid). Other suitable polymers are copolymers of any of acrylic acid and 2-alkyl acrylic acid monomers, copolymers of the foregoing monomers with maleic acid, olefinic polymers substituted with side chains containing free carboxylic acid groups, such as polyvinyl alcohol esterified with a diacid, triacid or polyacid (e.g., polyvinyl alcohol succinate), and the like. As will be appreciated by one of skill in the relevant art, the buffering adhesive composition of the disclosure can employ any high molecular weight polymer having partially neutralizable pendant carboxyl groups that is capable of maintaining the pH of a test product at less than about 6.0 in the phosphate buffer challenge test described in Example 1.
  • Polymers particularly well suited for use in an embodiment of the disclosure include polyacrylic acid (PAA) and polymethacrylic acid (PMA). Both PAA and PMA are available from, for example, Sigma-Aldrich Co., in a variety of forms, e.g., powder and solution, and in a range of molecular weights. Of the acrylic acid derivatives, PAA is preferred because it has the highest density of carboxylic acid sites per gram of compound and hence the highest extent of buffering per gram of compound. As used herein, “high molecular weight” PAA means greater than about 60,000 Daltons and as high as several million Daltons. The term has similar meanings for PMA and the other polymers described above.
  • As discussed above, these poly-acidic polymers can be partially neutralized to provide both the acid and salt components of the buffer system on the same molecule. Typical extents of neutralization are from about 20% to about 40%, preferably from about 25% to about 37% for PAA and similar values for other polymers. These ranges include all values within the end points, and particularly 28%, 31%, 34%, and 36%. One of ordinary skill in the art can readily determine the appropriate degree of neutralization for a particular polymer and use, particularly to achieve the desired pH buffering range. Partial neutralization of PAA may be achieved by mixing PAA (plus water if appropriate) with a stoichiometrically appropriate amount of a strong base (e.g., NaOH) until the desired degree of neutralization is achieved. Other polymers may be treated similarly. Partially neutralized polyacids such as PAA are also available commercially.
  • PAA and related polymers exist in both cross-linked and non cross-linked forms and the degree of cross-linking can be varied. Cross-linked PAA is known to be an excellent absorbent. The polymers used in the present disclosure, however, are preferably not cross-linked. The inventors have discovered that cross-linked PAA (for example) may be excessively absorbent, and its use in the present disclosure would lead to excessive swelling and possible rupture of the product in which it is being used. Moreover, non cross-linked PAA and related polymers are preferred because of their ability to form mucoadhesives to aid in the retention on the skin of the device with which the adhesive composition of the disclosure is used.
  • As stated, high molecular weight polymers, e.g., PAA and PMA, both provide effective pH buffering and absorb fluids such as perspiration, wound exudate, or fecal matter. More specifically, the polymers function similarly to hydrocolloids such as pectin and CMC when dispersed within an adhesive matrix. That is, they absorb and swell and form viscous solutions that provide mucoadhesion against a wearer's skin. As will be appreciated, the high molecular weight polymers may be the sole hydrocolloid component or in other embodiments, they may be combined with other hydrocolloids, depending on the application and desired fluid handling capabilities of the wound dressing or skin barrier.
  • In one embodiment of the disclosure, high molecular weight PAA is combined with polyisobutylene and either styrene-isoprene-styrene copolymer or polymer fibers (or both) for increased strength. In one such embodiment, the adhesive composition comprises high molecular weight PAA, polyisobutylene, and styrene-isoprene copolymer. In another such embodiment, the adhesive composition comprises high molecular weight PAA, polyisobutylene, styrene-isoprene copolymer and fibers such as cotton or preferably polyolefin such as polyethylene or polypropylene.
  • The adhesive component of the compositions of this disclosure may be any material that has pressure-sensitive adhesive properties with a strong affinity for the material of the fibers. It may be a single pressure-sensitive adhesive or a combination of two or more pressure-sensitive adhesives. Adhesives useful in the present disclosure include, for example, those based on natural rubbers, synthetic rubbers, styrene block copolymers, polyvinyl ethers, poly(meth)acrylates (including both acrylates and methacrylates), polyolefins and silicones. A particular adhesive believed to be a preferred material of choice for this disclosure is a polyolefin, namely, polyisobutylene (PIB), but other pressure-sensitive adhesive materials having similar properties are believed suitable.
  • The fibers in the adhesive composition may be any fibrous material known in the art but preferably are compatible with, and even have a strong affinity for, the tacky adhesive component. It has been found that polyolefins such as polyethylene and polypropylene are highly compatible with PIB and are easily wetted by that adhesive medium. Both are non-polar saturated hydrocarbons.
  • In one embodiment of the manufacture of the adhesive composition, a high molecular weight polymeric buffering adhesive such as PAA or PMA and a pressure-sensitive adhesive such as PIB are combined in a single mixing step. Other materials such as SIS and/or polypropylene fibers may additionally be combined in the single mixing step. This manufacturing embodiment has the benefit of avoiding multiple mixing steps, thereby saving time and minimizing equipment use. A preferred embodiment in this manufacture is the combination of the desired amounts of PAA, PIB, and SIS in a single mixing step.
  • Preferably such PIB is present as relatively high molecular weight PIB (molecular weight in the range of about 40,000 to 60,000). For example, a skin barrier for ostomy use would normally contain 60,000 molecular weight PIB in the range of 50 wt. % to 65 wt. % or 40,000 molecular weight PIB in the range of 40 wt. % to about 55 wt. %. Additionally, combinations of 40,000 molecular weight and 60,000 molecular weight PIB may also be used, such as 32.5 wt. % 40,000 molecular weight PIB and 32.5 wt. % 60,000 molecular weight PIB.
  • Preferably, the partially neutralized high molecular weight polyacid (e.g., PAA) comprises from about 20 wt. % to about 45 wt. % of the adhesive composition. The PIB component may comprise from about 40 wt. % to about 65 wt. % of the adhesive composition. The SIS component may comprise from about 0 wt. % to about 25 wt. % of the adhesive composition. Preferably, the adhesive composition comprises from about 20 wt. % to about 45 wt. % partially neutralized polyacrylic acid, from about 40 wt. % to about 55 wt. % PIB, and from about 5 wt. % to about 15 wt. % SIS. One preferred adhesive composition comprises about 45 wt. % partially neutralized PAA, about 40 wt. % PIB, and about 15 wt. % SIS. Another preferred adhesive composition comprises about 30 wt. % partially neutralized PAA, about 55 wt. % PIB, and about 15 wt. % SIS. Another preferred adhesive composition comprises about 54 wt. % PIB, about 6 wt. % polyethylene fibers, and about 40 wt. % 25% neutralized high molecular weight PAA. Still another preferred adhesive composition comprises about 51 wt. % PIB, about 20 wt. % SIS, about 2 wt. % polyethylene fibers, and about 27 wt. % 35% neutralized high molecular weight PAA. In the latter two compositions, the PIB is preferably Nippon Himol 4H as described below.
  • Whatever materials are chosen for the buffering adhesive composition of the disclosure, it is highly desirable that the composition be at least minimally absorptive. The buffering capability of the present compositions is related in part to their absorptive capability. If no absorption were to occur, the high molecular weight polymeric buffer would not be contacted by the wound exudate or fecal material and hence would not be effective. Although compositions having lower absorptive capacity are included within the present disclosure, the compositions of the disclosure should preferable have an absorptive capacity of at least about 0.15 g/cm2 as measured in the test of Example 1. The buffering capability of compositions having lower absorptive capacity is less optimal.
  • The following Examples describe the manufacture and testing of representative embodiments of the disclosure.
  • Example 1
  • Test Samples:
  • Test samples were prepared by heat compression of barrier materials to a thickness of 0.020 inches and were laminated between a removable release liner and a flexible backing film.
  • Materials
  • Polyisobutylene (PIB)
  • Oppanol® B10 with viscosity average molecular weight 40,000 produced by BASF
    Oppanol® B12 with viscosity average molecular weight 55,000 produced by BASF
    Nippon Himol 6H with viscosity average molecular weight 60,000 produced by JX Nippon Oil and Energy
    Nippon Himol 4H with viscosity average molecular weight 40,000 produced by JX Nippon Oil and Energy
  • Styrene-Isoprene-Styrene Block Copolymer (SIS)
  • Kraton™ D-1161P produced by Kraton Polymers
  • Polyolefin Fibers
  • Polyethylene Short Stuff Synthetic Pulp E380F supplied by MiniFIBERS, Inc.
    Polypropylene Short Stuff Synthetic Pulp Y600F supplied by MiniFIBERS, Inc.
  • Polyacrylic Acid Aqueous Solutions
  • Noverite™ K-702 25% aqueous solution with molecular weight 345,000 produced by Lubrizol
    ACUMER™ 1510 25% aqueous solution with molecular weight 60,000 produced by Dow
  • Partially Neutralized Polyacrylic Acid
  • Polyacrylic acid in water was neutralized to the desired degree by addition of aqueous sodium hydroxide. The resulting solution of partially neutralized polyacrylic acid was dried in aluminum trays at 150° C. for approximately 20 hours. The dried material was crushed and then ground in a hammer mill (Model JT, Homiloid Machine, Fitzpatrick Corporation). Laser light scattering particle size analysis of different batches showed mean particle sizes in the range from 70 to 150 microns.
    In addition, partially neutralized Polyacrylic Acid was obtained pre-neutralized in dry powder form:
    Aronvis AH-106X (35% neutralized Polyacrylic acid) produced by Toa Gosei.
  • Fluid Absorption and pH:
  • Fluid absorption was measured following the practice of standard EN 13726-1:2002 (Test methods for primary wound dressings—Part 1: Aspects of absorbency, Section 3.3). The hydrating fluid was normal saline (0.9% NaCl in water). The mass of fluid absorbed was measured by the weight gain in samples of 10 cm2 surface area exposed to 20 mL normal saline. Samples were maintained in an oven (37° C., 15% relative humidity) for fixed time periods. Surface pH measurements were performed on samples following fluid absorption using a calibrated pH meter and a flat pH probe (Ross® model 8135BN).
  • pH Buffer Challenge:
  • A stock buffer solution (100 mM in Phosphate, 0.9% NaCl, pH 7.4) was prepared. Lower phosphate concentration buffers were prepared by dilution of the stock buffer with appropriate volumes of 0.9% NaCl. A 10 cm2 surface of the barrier was exposed to 10 mL of buffer challenge solution.
  • A series of formulations based on PIB, polyethylene fibers and partially neutralized polyacrylic acid (with two different molecular weights and two different degrees of neutralization) were prepared.
  • Example 2
  • Compositions were prepared using a Brabender Type REE6 mixer at 85° C. The required amounts of polyethylene fibers and partially neutralized polyacrylic acid were pre-blended. The required weight of PIB was added to the mixer and was mixed at 36 rpm for 2 minutes. The pre-blended fibers and powder were added over the course of 3 minutes while mixing at 36 rpm. The mixing chamber was sealed and vacuum was applied and mixing was continued for 15 minutes. Vacuum was released and the mixtures were removed from the mixer and allowed to equilibrate at room conditions before any testing was undertaken. Table 1 below shows compositions prepared in this fashion with weight percentages of the indicated ingredients along with testing results for these compositions. In Table 1 and Table 2 below, the 6 Hour and 24 Hour Buffer Challenges used a 100 mM phosphate buffer at pH 7.4 in 0.9% NaCl solution.
  • TABLE 1
    Poly- 6 Hour 24 Hour 6 Hour 24 Hour
    isobutylene Poly- Poly- Percent Fluid 6 Hour Fluid 24 Hour Buffer Buffer
    Oppanol ethylene acrylate Polyacrylic Neutral- Absorption Surface Absorption Surface Challenge Challenge
    B12 fiber Buffer acid source ized g/cm2 pH g/cm2 pH Surface pH Surface pH
    65.0% 4.0% 31.0% ACUMER ™ 1510 37.5 0.015 4.82 0.019 4.97 7.29 7.00
    51.0% 4.0% 45.0% ACUMER ™ 1510 25 0.184 4.26 0.435 4.17 5.10 4.99
    52.6% 6.3% 41.1% Noverite ™ K-702 25 0.209 4.45 0.524 4.41 5.39 5.32
    48.5% 6.5% 45.0% ACUMER ™ 1510 37.5 0.057 4.74 0.219 4.68 6.26 5.53
    65.0% 5.0% 30.0% ACUMER ™ 1510 25 0.033 4.38 0.123 4.22 6.65 5.91
    47.0% 8.0% 45.0% ACUMER ™ 1510 37.5 0.034 4.76 0.091 4.72 6.56 5.48
    51.9% 8.0% 40.1% ACUMER ™ 1510 25 0.084 4.25 0.247 4.21 5.89 5.21
    62.0% 8.0% 30.0% ACUMER ™ 1510 25 0.031 4.39 0.047 4.38 6.79 6.95
    47.0% 8.0% 45.0% Noverite ™ K-702 25 0.222 4.34 0.576 4.43 5.37 5.10
    65.0% 4.0% 31.0% ACUMER ™ 1510 25 0.074 4.23 0.200 4.23 6.38 5.32
    65.0% 4.0% 31.0% Noverite ™ K-702 25 0.123 4.44 0.306 4.45 5.98 5.53
    47.0% 8.0% 45.0% Noverite ™ K-702 37.5 0.170 4.81 0.466 4.87 5.71 5.67
    62.0% 8.0% 30.0% Noverite ™ K-702 25 0.057 4.51 0.246 4.83 6.91 5.78
    58.6% 4.0% 37.4% ACUMER ™ 1510 37.5 0.030 4.73 0.085 4.82 6.96 6.24
    51.0% 4.0% 45.0% Noverite ™ K-702 37.5 0.237 4.81 0.559 4.88 5.62 5.55
    53.8% 8.0% 38.2% Noverite ™ K-702 37.5 0.076 5.05 0.316 4.93 6.54 5.76
    62.0% 8.0% 30.0% Noverite ™ K-702 37.5 0.030 5.22 0.040 5.01 7.28 7.08
    62.0% 8.0% 30.0% ACUMER ™ 1510 37.5 0.031 4.81 0.029 4.51 7.40 7.24
    51.0% 4.0% 45.0% Noverite ™ K-702 25 0.299 4.42 0.616 4.38 5.31 5.37
    47.0% 8.0% 45.0% ACUMER ™ 1510 25 0.183 4.21 0.365 4.20 5.53 5.07
    65.0% 5.0% 30.0% Noverite ™ K-702 37.5 0.027 5.03 0.089 5.02 7.19 6.47
    62.0% 8.0% 30.0% ACUMER ™ 1510 37.5 0.028 4.76 0.029 4.76 7.32 7.18
    51.0% 4.0% 45.0% ACUMER ™ 1510 37.5 0.107 4.74 0.214 4.72 6.45 5.33
    65.0% 4.0% 31.0% Noverite ™ K-702 37.5 0.062 4.89 0.198 4.92 7.01 5.96
  • Example 3
  • A second series of formulations based on PIB (two different molecular weights), Styrene-Isoprene-Styrene copolymer and partially neutralized polyacrylic acid (25% neutralized Noverite K-702) were prepared.
  • Compositions were prepared using a Brabender Type REE6 mixer at 140° C. The required weight of SIS was added to the mixer and was mixed at 36 rpm for 7 minutes. The required amount of PIB and mixing was continued at 36 rpm. The mixer speed was increased to 100 rpm and mixing was continued for another 11 minutes. The required amount of partially neutralized polyacrylic acid (25% degree of neutralization) was added and mixing was continued for 4 minutes. The mixing chamber was sealed and vacuum was applied and mixing was continued for 16 minutes. Vacuum was released and the mixtures were removed from the mixer and allowed to equilibrate at room conditions before any testing was undertaken. Tests were performed as in Example 1. Table 2 below shows compositions prepared in this fashion with weight percentages of the indicated ingredients along with testing results for these compositions.
  • TABLE 2
    4H PIB 40,000 6H PIB 60,000 Poly- 6 Hour 24 Hour 24 Hour
    molecular molecular Styrene-Isoprene- acrylate Absorption 6 Hour Absorption 24 Hour Buffer
    weight weight Styrene Copolymer Buffer g/cm2 pH g/cm2 pH Challenge pH
    55.0% 0.0% 15.0% 30.0% 0.231 4.48 0.378 4.49 5.82
    55.0% 0.0% 15.0% 30.0% 0.171 4.5 0.386 4.47 5.98
    0.0% 40.0% 15.0% 45.0% 0.178 4.48 0.307 4.47 6.27
    45.0% 0.0% 10.0% 45.0% 0.283 4.47 0.474 4.45 5.63
    40.0% 0.0% 15.0% 45.0% 0.318 4.45 0.597 4.46 5.44
    0.0% 50.0% 5.0% 45.0% 0.163 4.51 0.356 4.48 6.17
    40.0% 0.0% 15.0% 45.0% 0.290 4.46 0.464 4.47 5.51
    0.0% 55.0% 15.0% 30.0% 0.096 4.44 0.218 4.5 6.54
    64.8% 0.2% 5.0% 30.0% 0.087 4.48 0.343 4.51 5.96
    0.0% 44.6% 10.4% 45.0% 0.092 4.45 0.183 4.51 6.64
    32.5% 32.5% 5.0% 30.0% 0.125 4.44 0.353 4.54 6.06
    53.0% 0.0% 10.0% 37.0% 0.123 4.45 0.342 4.53 6.06
    0.0% 65.0% 5.0% 30.0% 0.053 4.49 0.18 4.53 6.64
    31.9% 25.6% 5.0% 37.5% 0.139 4.44 0.382 4.51 5.9
    0.0% 47.5% 15.0% 37.5% 0.051 4.5 0.069 4.55 7.06
    25.4% 32.1% 5.0% 37.5% 0.077 4.51 0.176 4.53 6.58
    27.5% 27.5% 15.0% 30.0% 0.118 4.47 0.295 4.53 6.29
    0.0% 50.0% 5.0% 45.0% 0.109 4.45 0.28 4.55 6.37
    26.2% 33.8% 10.0% 30.0% 0.151 4.46 0.351 4.57 6.12
    65.0% 0.0% 5.0% 30.0% 0.139 4.47 0.365 4.54 6.03
    0.0% 65.0% 5.0% 30.0% 0.075 4.49 0.178 4.5 6.65
    0.0% 55.0% 15.0% 30.0% 0.087 4.49 0.14 4.55 6.73
    50.0% 0.0% 5.0% 45.0% 0.165 4.46 0.375 4.54 5.93
    50.0% 0.0% 5.0% 45.0% 0.174 4.47 0.386 4.5 5.84
  • Example 4
  • A third series of formulations based on PIB, Styrene-Isoprene-Styrene copolymer, polyethylene fibers and partially neutralized polyacrylic acid (35% Aronvis AH-106X) were prepared. A masterbatch composed of 50% PIB (Nippon 4H) and 50% Styrene-Isoprene-Styrene copolymer was prepared using a Brabender Type REE6 mixer at 140° C. The required weight of SIS was added to the mixer and was mixed at 36 rpm for 7 minutes. The required amount of PIB was added as mixing was continued at 36 rpm. The mixer speed was then increased to 100 rpm and mixing was continued for another 11 minutes. The masterbatch was removed from the mixer and cooled to room temperature before further use.
  • Compositions were prepared using a Brabender Type REE6 mixer at 85° C. The required amounts of polyethylene fibers and partially neutralized polyacrylic acid were pre-blended. The required amount of 50:50 masterbatch prepared as described above was added to the mixer and was mixed at 36 rpm for 4 minutes. The required amount of additional PIB was added to the mixer and was mixed at 36 rpm for 4 minutes. The pre-blended fibers and powder were then added over the course of 3 minutes while mixing at 36 rpm. Mixing continued for a further 2 minutes, following which the mixing chamber was sealed and vacuum was applied while mixing was continued for 12 minutes. Vacuum was released and the mixture was removed from the mixer and allowed to equilibrate at room conditions before any testing was undertaken. Tests were performed as in Example 1. Table 3 below shows compositions prepared in this fashion with weight percentages of the indicated ingredients along with testing results for these compositions.
  • TABLE 3
    Polyacrylate 6 hour 24 hour 24 Hour
    Nippon Styrene-Isoprene- PE Buffer Aronvis Absorption 6 Hour Absorption 24 Hour buffer
    4H PIB Styrene Copolymer fibers AH-106X g/cm2 pH g/cm2 pH challenge pH
    48.9% 22.0% 2.0% 27.1% 0.213 4.64 0.293 4.63 6.07
    55.0% 16.4% 3.8% 24.8% 0.183 4.65 0.184 4.65 6.21
    53.0% 25.0% 2.0% 20.0% 0.065 4.61 0.072 4.68 6.81
    51.0% 15.0% 4.0% 30.0% 0.281 4.64 0.359 4.65 5.89
    55.0% 21.0% 4.0% 20.0% 0.040 4.61 0.034 4.68 7.04
    52.8% 15.2% 2.0% 30.0% 0.265 4.59 0.332 4.63 5.99
    43.0% 25.0% 2.0% 30.0% 0.239 4.64 0.326 4.59 6.03
    55.0% 20.2% 2.0% 22.8% 0.099 4.63 0.091 4.64 6.68
    41.0% 25.0% 4.0% 30.0% 0.257 4.75 0.356 4.58 5.92
    47.4% 19.4% 3.1% 30.0% 0.297 4.75 0.390 4.6 5.89
    52.0% 25.0% 3.0% 20.0% 0.053 4.74 0.062 4.65 6.81
    48.3% 25.0% 4.0% 22.7% 0.116 4.74 0.186 4.61 6.29
  • Example 5
  • A formulation based on PIB, Styrene-Isoprene-Styrene copolymer, Polypropylene fibers and partially neutralized polyacrylic acid (35% neutralized Aronvis AH-106X) was prepared in a single step mixing process.
  • The composition was prepared using a Brabender Type REE6 mixer at 140° C. The required weight of SIS was added to the mixer and was mixed at 36 rpm for 7 minutes. The required amount of PIB and mixing was continued at 36 rpm. The mixer speed was increased to 100 rpm and mixing was continued for another 11 minutes. The required amounts of partially neutralized polyacrylic acid and Polypropylene fibers were pre-blended and the blend was added and mixing was continued for 4 minutes. The mixing chamber was sealed and vacuum was applied and mixing was continued for 16 minutes. Vacuum was released and the mixtures were removed from the mixer and allowed to equilibrate at room conditions before any testing was undertaken. Testing was done as in Example 1 and results are shown in Table 4 below.
  • TABLE 4
    Polypropylene
    4H PIB 40,000 Fiber Short Polyacrylate 6 Hour 24 Hour 24 Hour
    molecular Styrene-Isoprene- Stuff Synthetic Buffer Aronvis Absorption 6 Hour Absorption 24 Hour Buffer
    weight Styrene Copolymer Pulp Y600F AH-106X g/cm2 pH g/cm2 pH Challenge pH
    55% 14% 4% 27% 0.332 4.59 0.474 4.63 5.98
  • High molecular weight polymers such as those set forth above provide both enhanced pH buffering capacity and absorption with reduced skin irritation. The inventors have surprisingly discovered that low molecular weight acids, such as citric acid, are unsuitable for buffer systems in the present disclosure. Although such low molecular weight acids function acceptably as buffers, low molecular weight acid buffer systems cause unacceptable irritation to the user's skin for use as contemplated herein. When a buffering adhesive compositions similar to those of the disclosure but using a citric acid/citrate buffer instead of a high molecular weight polymer buffer was used in an adhesive dressing on human subjects, the subjects developed punctate ulcers under the dressing. The test results are shown below. Such an adhesive composition would be unsuitable for medical use. This result was both surprising and unexpected. The evaluation of a citric acid buffering system is described in Example 6 below.
  • Example 6
  • In 1968, Lanman et al., reported that several days of repeated exposures produced a method to discriminate among mildly irritating cosmetic type products. With modification including shorter time periods (e.g., 21 days) this method has remained the standard test for determining a product's potential for mild cutaneous irritation. The methodology involves 21 consecutive daily applications under occlusion. A 1% sodium lauryl sulfate (SLS) solution applied on a non-woven pad served as the positive control while preservative-free 0.9% sodium chloride applied in a similar manner served as the negative control. This standard test was used to assess the irritation potential of various barrier formulations applied directly to skin for 21 consecutive applications. Because the barrier materials are self-adhesive, it was possible to partially differentiate between the contribution from irritation due to mechanical properties (skin stripping) and chemical irritation, by comparing irritation resulting from direct application with that observed when the barrier was isolated from the skin using a non-woven pad moistened with sterile normal saline as well as using barriers constructed with and without buffering material.
  • A sufficient number of normal volunteer subjects was recruited to ensure completion with 30. Each subject was exposed to all test materials and the sites were randomized using a standard Latin Square design. Graders were blinded to the identity of the materials. Materials were reapplied to the same site for 21 consecutive days or until a discontinuation score was reached. The irritation data was treated using rank sum analysis. Rank sums range from 1 to 10 with higher numbers indicating more irritation.
  • Formulations used in the irritation testing are described below;
  • Citrate Barrier
  • Oppanol ® B12 44.0%
    TPC Group TPC1285 liquid PIB 7.0%
    Polyethylene Fiber 3.5%
    Pectin 8.5%
    Sodium Carboxymethyl Cellulose 17.0%
    Monosodium citrate Anhydrous 16.0%
    Trisodium Citrate Dihydrate 4.0%
  • PAA Barrier
  • Oppanol ® B12 55.0%
    TPC Group TPC1285 liquid PIB 8.7%
    Polyethylene Fiber 4.4%
    Partially neutralized PAA 31.9%
  • Using this standard methodology, the irritation potential of the formulation containing 20% citrate barrier (mean rank 9.59) was similar to that of the positive control (mean rank 9.27). Only the barrier formulation containing citrate caused irritation accompanied by focal erosions (punctate lesions), which was different from the more uniform irritation typically observed with exposure to SLS. The barrier formulated with PAA (mean rank 6.70) was significantly less irritating that either the positive control or the citrate buffer formulation. The slight irritation observed due to repeated exposure to the PAA barrier formulation was more uniform ‘glazing’ characteristic of repeated mechanical trauma, i.e., tape stripping. Both of these groups were different from the negative control (mean rank 2.68). The PAA buffer applied in petrolatum (31.8% PAA in petrolatum) was non-irritating, indicating a lack of inherent chemical irritation due to repeated exposure to PAA. This observation is consistent with the interpretation that the minor irritation observed with the barrier formulated with PAA is due to repeated mechanical damage.
  • An embodiment of the present disclosure contemplates the use of a high molecular weight polymeric buffer incorporated into the adhesive layer of a wound dressing. The wound dressing preferably includes a flexible outer layer such as a film. A hydrocolloid layer is on an inner side of the outer layer and contains the inventive high molecular weight polymeric buffer along with, optionally, an additional hydrocolloid such as CMC or pectin. As will be appreciated, the hydrocolloid layer is in direct contact with the wound bed.
  • In an embodiment, the wound dressing includes an adhesive component having a very high cohesive strength when hydrated to avoid potential disintegration of the dressing components in the wound bed. As will be appreciated, non-adhesive wound dressings incorporating the inventive buffer may also be possible.
  • A formulation suitable for a self-adhesive wound dressing would be, for example, formulation 7 in Table 2 (40% PIB, 15% SIS, 45% PAA) which has high cohesive strength due to the relatively high SIS content along with high fluid absorption and buffering properties, useful for managing wound exudate. Those of ordinary skill in the art would know how to use this formulation in preparation of a self-adhesive wound dressing.
  • Another embodiment of the present disclosure contemplates the use of a high molecular weight buffer incorporated into an ostomy skin barrier. The skin barrier may be permanently attached to an ostomy pouch (a “one step” or one piece arrangement) or may be separately attached using a flange clip system (a two piece arrangement). This embodiment of the disclosure will maintain the pH of the peristomal skin closer to the normal skin pH range of about 4.0 to about 5.5, thus reducing or eliminating the occurrence of irritation in the peristomal area.
  • Useful example formulations for ostomy skin barriers include those containing either polyethylene fibers or SIS. For example, formulation 3 of Table 1 combines desirable fluid handling ability with excellent pH control. Formulation 1 in Table 2 is an example of a formulation incorporating SIS with similar fluid handling and pH control. Those of ordinary skill in the art would know how to use this formulation in preparation of an ostomy skin barrier.
  • Also included in the present disclosure are methods of making and using the above-described high molecular weight polymeric buffer compositions. The making of the compositions of the disclosure is described above. The compositions may be used to manufacture any skin-adhering device by applying to a side or surface of the device an amount of the composition effective to securely attach the device to the skin of the intended user.
  • While the invention has been described with reference to the preferred embodiments, it will be understood by those skilled in the art that various obvious changes may be made, and equivalents may be substituted for elements thereof, without departing from the essential scope of the present invention. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed.

Claims (21)

What is claimed is:
1. An adhesive composition for a skin-adhering device comprising a high molecular weight polymeric buffer which provides both pH buffering and fluid absorption.
2. The adhesive composition of claim 1 wherein the high molecular weight polymeric buffer is a partially neutralized high molecular weight polymeric acid selected from the group consisting of polyacrylic acid, poly(2-alkyl acrylic acid), copolymers of acrylic acid and 2-alkyl acrylic acid monomers, copolymers of acrylic acid and 2-alkyl acrylic acid monomers with maleic acid, and olefinic polymers substituted with side chains containing free carboxylic acid groups, wherein alkyl is from one to five carbons in length and may be straight chain or branched chain.
3. The adhesive composition of claim 1 wherein the high molecular weight polymeric buffer is partially neutralized high molecular weight polyacrylic acid.
4. The adhesive composition of claim 3 wherein the degree of neutralization of the partially neutralized high molecular weight polyacrylic acid is from about 20% to about 40%.
5. The adhesive composition of claim 1 which further comprises a pressure-sensitive adhesive selected from the group consisting of natural rubbers, synthetic rubbers, styrene block copolymers, polyvinyl ethers, poly(meth)acrylates (including both acrylates and methacrylates), polyolefins and silicones.
6. The adhesive composition of claim 5 wherein the pressure-sensitive adhesive is polyisobutylene.
7. The adhesive composition of claim 1 which further comprises styrene-isoprene-styrene block copolymer.
8. The adhesive composition of claim 1 which further comprises fibers selected from the group consisting of cotton fibers, polyethylene fibers, and polypropylene fibers.
9. A wound dressing comprising:
a flexible outer layer; and
a high molecular weight polymeric buffering adhesive applied to a side of the flexible outer layer, said adhesive providing pH buffering and fluid absorption.
10. The wound dressing of claim 9 wherein the high molecular weight polymeric buffer is a partially neutralized high molecular weight polymeric acid selected from the group consisting of polyacrylic acid, poly(2-alkyl acrylic acid), copolymers of acrylic acid and 2-alkyl acrylic acid monomers, copolymers of acrylic acid and 2-alkyl acrylic acid monomers with maleic acid, and olefinic polymers substituted with side chains containing free carboxylic acid groups, wherein alkyl is from one to five carbons in length and may be straight chain or branched chain.
11. The wound dressing of claim 10 wherein the high molecular weight polymeric buffer is partially neutralized high molecular weight polyacrylic acid.
12. The wound dressing of claim 11 wherein the degree of neutralization of the partially neutralized high molecular weight polyacrylic acid is from about 20% to about 40%.
13. An ostomy skin barrier having an adhesive including a high molecular weight polymeric buffer to provide pH buffering and fluid absorption.
14. The ostomy skin barrier of claim 13 wherein the high molecular weight polymeric buffer is a partially neutralized high molecular weight polymeric acid selected from the group consisting of polyacrylic acid, poly(2-alkyl acrylic acid), copolymers of acrylic acid and 2-alkyl acrylic acid monomers, copolymers of acrylic acid and 2-alkyl acrylic acid monomers with maleic acid, and olefinic polymers substituted with side chains containing free carboxylic acid groups, wherein alkyl is from one to five carbons in length and may be straight chain or branched chain.
15. The ostomy skin barrier of claim 14 wherein the high molecular weight polymeric buffer is partially neutralized high molecular weight polyacrylic acid.
16. The ostomy skin barrier of claim 15 wherein the degree of neutralization of the partially neutralized high molecular weight polyacrylic acid is from about 20% to about 40%.
17. A method of making a buffering adhesive composition for a skin-adhering device that provides both pH buffering and fluid absorption which comprises combining a pressure-sensitive adhesive and a high molecular weight polymeric buffer in a single step mixing process.
18. The method of claim 17 wherein the high molecular weight polymeric buffer is a partially neutralized high molecular weight polymeric acid selected from the group consisting of polyacrylic acid, poly(2-alkyl acrylic acid), copolymers of acrylic acid and 2-alkyl acrylic acid monomers, copolymers of acrylic acid and 2-alkyl acrylic acid monomers with maleic acid, and olefinic polymers substituted with side chains containing free carboxylic acid groups, wherein alkyl is from one to five carbons in length and may be straight chain or branched chain and the pressure sensitive adhesive is selected from the group consisting of natural rubbers, synthetic rubbers, styrene block copolymers, polyvinyl ethers, poly(meth)acrylates (including both acrylates and methacrylates), polyolefins and silicones, and mixtures thereof.
19. The method of claim 18 wherein the high molecular weight polymeric buffer is selected from the group consisting of high molecular weight polyacrylic acid and high molecular weight polymethacrylic acid and the pressure-sensitive adhesive comprises polyisobutylene.
20. The method of claim 19 in which styrene-isobutylene-styrene block copolymer is also combined with the high molecular weight polymeric buffer and the pressure-sensitive adhesive in the single-step mixing process.
21. The method of claim 20 in which polypropylene fibers are also combined with the high molecular weight polymeric buffer and pressure-sensitive adhesive in the single-step mixing process.
US13/778,497 2012-02-29 2013-02-27 Buffered adhesive compositions for skin-adhering products and methods of making same Abandoned US20130226063A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/778,497 US20130226063A1 (en) 2012-02-29 2013-02-27 Buffered adhesive compositions for skin-adhering products and methods of making same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604663P 2012-02-29 2012-02-29
US201261668178P 2012-07-05 2012-07-05
US13/778,497 US20130226063A1 (en) 2012-02-29 2013-02-27 Buffered adhesive compositions for skin-adhering products and methods of making same

Publications (1)

Publication Number Publication Date
US20130226063A1 true US20130226063A1 (en) 2013-08-29

Family

ID=49003807

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/778,497 Abandoned US20130226063A1 (en) 2012-02-29 2013-02-27 Buffered adhesive compositions for skin-adhering products and methods of making same
US13/778,538 Active 2034-07-14 US9763833B2 (en) 2012-02-29 2013-02-27 Buffered adhesive compositions for skin-adhering medical products
US15/680,524 Active 2033-04-14 US10434015B2 (en) 2012-02-29 2017-08-18 Buffered adhesive compositions for skin-adhering medical products
US16/556,458 Active 2033-04-11 US11147716B2 (en) 2012-02-29 2019-08-30 Buffered adhesive compositions for skin-adhering medical products
US17/409,180 Active 2033-05-14 US11819389B2 (en) 2012-02-29 2021-08-23 Buffered adhesive compositions for skin-adhering medical products

Family Applications After (4)

Application Number Title Priority Date Filing Date
US13/778,538 Active 2034-07-14 US9763833B2 (en) 2012-02-29 2013-02-27 Buffered adhesive compositions for skin-adhering medical products
US15/680,524 Active 2033-04-14 US10434015B2 (en) 2012-02-29 2017-08-18 Buffered adhesive compositions for skin-adhering medical products
US16/556,458 Active 2033-04-11 US11147716B2 (en) 2012-02-29 2019-08-30 Buffered adhesive compositions for skin-adhering medical products
US17/409,180 Active 2033-05-14 US11819389B2 (en) 2012-02-29 2021-08-23 Buffered adhesive compositions for skin-adhering medical products

Country Status (11)

Country Link
US (5) US20130226063A1 (en)
EP (3) EP3622971A1 (en)
JP (3) JP6092243B2 (en)
AU (2) AU2013226154B2 (en)
CA (2) CA2851868A1 (en)
DK (1) DK2819627T3 (en)
ES (1) ES2768599T3 (en)
HU (1) HUE047625T2 (en)
LT (1) LT2819627T (en)
PL (1) PL2819627T3 (en)
WO (2) WO2013130566A2 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017530216A (en) * 2014-08-20 2017-10-12 ホリスター・インコーポレイテッドHollister Incorporated Buffer adhesive composition for skin adhesive medical device
WO2019091528A1 (en) * 2017-11-08 2019-05-16 Coloplast A/S An adhesive wafer with a neutralizer matrix
WO2019165751A1 (en) * 2018-02-28 2019-09-06 江苏金太阳纺织科技股份有限公司 Buffering agent for balancing ph value of fabric and preparation method therefor
US10968543B2 (en) 2011-12-01 2021-04-06 Convatec Technologies Inc. Wound dressing for use in vacuum therapy
US11039950B2 (en) 2015-10-14 2021-06-22 Convatec Technologies Inc. Medical device with an opening system
US11076978B2 (en) 2009-09-11 2021-08-03 Convatec Technologies Inc. Controlled discharge ostomy appliance and shield therefor
US11076979B2 (en) 2008-11-19 2021-08-03 Convatec Technologies Inc. Ostomy pouch appliance
US11103621B2 (en) 2011-09-02 2021-08-31 Convatec Ltd Discharge solidifier and malodour control
US11116884B2 (en) 2010-12-08 2021-09-14 Convatec Technologies Inc. Integrated system for assessing wound exudates
US11135315B2 (en) 2010-11-30 2021-10-05 Convatec Technologies Inc. Composition for detecting biofilms on viable tissues
US11166837B2 (en) 2010-09-30 2021-11-09 Convatec Technologies Inc. Ostomy pouch with filtering system
US11166838B2 (en) 2007-06-12 2021-11-09 Convatec Technologies Inc. Ostomy appliance
US11241339B2 (en) 2011-11-29 2022-02-08 Convatec Inc. Perforated binder for laminated wound dressing
US11241525B2 (en) 2010-12-08 2022-02-08 Convatec Technologies Inc. Wound exudate monitor accessory
US11266774B2 (en) 2016-07-08 2022-03-08 Convatec Technologies Inc. Fluid collection apparatus
US11278640B2 (en) 2016-05-04 2022-03-22 Coloplast A/S Adhesive wafer with a neutralizer matrix
US11286601B2 (en) 2012-12-20 2022-03-29 Convatec Technologies, Inc. Processing of chemically modified cellulosic fibres
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing
US11426485B2 (en) 2009-07-07 2022-08-30 Convatec Technologies Inc. Pressure sensitive adhesives with amphiphilic copolymer
US11452808B2 (en) 2016-07-08 2022-09-27 Convatec Technologies Inc. Fluid flow sensing
US11458044B2 (en) 2008-09-29 2022-10-04 Convatec Technologies Inc. Wound dressing
US11491254B2 (en) 2017-11-08 2022-11-08 Coloplast A/S Adhesive wafer with a neutralizer matrix
US11583430B2 (en) 2011-09-02 2023-02-21 Convatec Ltd. Skin contact material
US11590017B2 (en) 2019-04-25 2023-02-28 Convatec Technologies Inc. Ostomy wafers incorporating adhesives, ostomy devices including the same, and methods of applying ostomy wafers and ostomy devices
US11596554B2 (en) 2016-07-08 2023-03-07 Convatec Technologies Inc. Flexible negative pressure system
US11628093B2 (en) 2008-05-08 2023-04-18 Convatec Technologies, Inc. Wound dressing
US11638658B2 (en) 2019-04-25 2023-05-02 Convatec Technologies, Inc. Ostomy wafers incorporating adhesives and foam layers, ostomy devices including the same, and methods of applying ostomy wafers and ostomy devices
US11679020B2 (en) 2019-04-25 2023-06-20 Convatec Technologies, Inc. Perforated chamber ostomy wafers, ostomy devices including the same, and methods of applying ostomy wafers and ostomy devices
US11723808B2 (en) 2016-03-30 2023-08-15 Convatec Technologies Inc. Detecting microbial infections in wounds
US11737906B2 (en) 2019-02-07 2023-08-29 Convatec Technologies, Inc. Adjustable convex ostomy device
US11740241B2 (en) 2016-03-30 2023-08-29 Synovo Gmbh Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems
US11890218B2 (en) 2014-04-24 2024-02-06 Convatec Technologies Inc. Ostomy pouch filter system

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013226154B2 (en) 2012-02-29 2015-07-09 Hollister Incorporated Buffered adhesive compositions for skin-adhering products and methods of making same
US10470936B2 (en) 2012-02-29 2019-11-12 Hollister Incorporated Buffered adhesive compositions for skin-adhering medical products
WO2016160315A1 (en) * 2015-03-31 2016-10-06 Dow Global Technologies Llc Flooding compounds for telecommunication cables
WO2019091532A1 (en) 2017-11-08 2019-05-16 Coloplast A/S Kit of parts and a complementary-material element for an ostomy appliance
CA3079131A1 (en) 2017-11-09 2019-05-16 11 Health and Technologies Inc. Ostomy monitoring system and method
CA3080013C (en) * 2017-11-15 2023-08-22 Hollister Incorporated Buffered adhesive compositions for skin-adhering medical products
DE102017130893A1 (en) * 2017-12-21 2019-06-27 Paul Hartmann Ag pH regulating wound dressing
USD893514S1 (en) 2018-11-08 2020-08-18 11 Health And Technologies Limited Display screen or portion thereof with graphical user interface

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750136A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US20040156886A1 (en) * 2001-06-12 2004-08-12 Yasuhisa Kose Sheet-like patch agent
US20050215727A1 (en) * 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US20070219287A1 (en) * 2006-03-16 2007-09-20 Hollister Incorporated Hydrocolloid-containing adhesive composition having network of fibrillated polymeric fibers
US20130316042A1 (en) * 2010-06-25 2013-11-28 Cadbury Adams Mexico, S. De R.L. De C.V. Enhanced release of lipophilic ingredients from chewing gum with hydrocolloids

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3339546A (en) 1963-12-13 1967-09-05 Squibb & Sons Inc Bandage for adhering to moist surfaces
GB1576522A (en) 1977-05-24 1980-10-08 Colorplast International A S Sealing material for ostomy devices
US4192785A (en) 1977-06-08 1980-03-11 E. R. Squibb & Sons, Inc. Ostomy adhesive
GB2038661B (en) 1978-11-20 1982-12-01 Searle & Co Surgical sealant composition
DK147035C (en) 1980-12-05 1984-09-03 Coloplast As Skin Barrier
US4650817A (en) 1982-07-16 1987-03-17 C. R. Bard, Inc. Physiologically compatible adhesive composition
US4551490A (en) 1983-06-27 1985-11-05 E. R. Squibb & Sons, Inc. Adhesive composition resistant to biological fluids
PH26954A (en) 1985-05-15 1992-12-03 Procter & Gamble Disposable absorbent articles
JPS62111918A (en) * 1985-11-08 1987-05-22 Nitto Electric Ind Co Ltd Hydrous application agent
SE455466C (en) 1986-03-10 1993-06-17 Moelnlycke Ab Conveyor Belt for Dangerous Sores
US4738257A (en) 1986-06-11 1988-04-19 Hollister Incorporated Occlusive wound care dressing
CA1326416C (en) 1986-08-25 1994-01-25 Ralph Xavier Ewall Polymeric wound dressings
DK154747C (en) 1986-10-17 1989-05-08 Coloplast As BANDAGE WITH A SKIN-FRIENDLY, WATER-ABSORBING CLOTH DISC WHICH IS ON THE SURFACE IS STRONGLY ASSOCIATED WITH A NON-CLASSIC COVERAGE AND ON THE OTHER WITH A REMOVABLE PROTECTIVE COVER
US4793337A (en) 1986-11-17 1988-12-27 E. R. Squibb & Sons, Inc. Adhesive structure and products including same
US4813942A (en) 1987-03-17 1989-03-21 Bioderm, Inc. Three step wound treatment method and dressing therefor
US4952618A (en) * 1988-05-03 1990-08-28 Minnesota Mining And Manufacturing Company Hydrocolloid/adhesive composition
US5059169A (en) 1989-07-07 1991-10-22 C. R. Bard, Inc. High-friction prostatic stent
ES2071297T3 (en) 1989-12-28 1995-06-16 Minnesota Mining & Mfg MATERIAL COMPOSED OF A GEL DISPERSED IN AN ADHESIVE MATRIX AND METHOD FOR PREPARING SUCH COMPOSITE MATERIAL.
JPH04166016A (en) * 1990-05-12 1992-06-11 Arakawa Chem Ind Co Ltd Method for cultivating plant effectively used as countermeasure against acid rain
US5705551A (en) 1991-12-06 1998-01-06 Avery Dennison Corporation Elastomeric pressure-sensitive adhesive compositions exhibiting good cutting performance
JPH06200A (en) * 1992-06-19 1994-01-11 Teikoku Seiyaku Co Ltd Wound protective material
CA2104046C (en) 1992-10-05 1998-09-15 Yen-Lane Chen Adhesive compositions, wound dressings and methods
DK169711B1 (en) 1993-01-15 1995-01-23 Coloplast As A dressing
DK44193D0 (en) 1993-04-20 1993-04-20 Euromed I S SPECIAL CONNECTION AND ADMINISTRATIVE TO A SPECIAL CONNECTION OR SIMILAR
JP2811540B2 (en) * 1993-10-20 1998-10-15 呉羽化学工業株式会社 Gas barrier film and method for producing the same
DE4416927C1 (en) 1994-05-13 1995-08-31 Lohmann Therapie Syst Lts Device for release of active agents from melt-type adhesive
AU4282096A (en) 1994-11-15 1996-06-06 Osmotics Corporation Skin care compositions and methods
JP3471122B2 (en) 1995-04-26 2003-11-25 アルケア株式会社 Medical adhesive compound
US5609585A (en) 1995-08-01 1997-03-11 Hollister Incorporated Wafer having adhesive skin barrier layer
FR2761889B1 (en) 1997-04-11 1999-12-31 Oreal PHARMACEUTICAL, COSMETIC OR DERMO-PHARMACEUTICAL PATCH FOR THE DELIVERY OF SEVERAL ACTIVE COMPOUNDS OF DIFFERENT NATURE
DK99397A (en) 1997-08-29 1999-05-05 Coloplast As Adhesive and use of this agent
US6639120B1 (en) 1997-12-12 2003-10-28 Kimberly-Clark Worldwide, Inc. Structure having balanced pH profile
ZA9810779B (en) 1997-12-12 1999-09-21 Kimberly Clark Co Structure having balanced pH profile.
JP4723093B2 (en) 1999-03-17 2011-07-13 コロプラスト アクティーゼルスカブ Pressure sensitive adhesive composition
DE19918106A1 (en) 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermal patches containing basic or neutral drug include adhesive (meth)acrylic acid polymer in alkali(ne earth) metal salt form
DE60001836T3 (en) 1999-07-15 2008-02-07 Coloplast A/S ostomy appliance
GB9920167D0 (en) 1999-08-25 1999-10-27 Avery Dennison Corp Pressure sensitive adhesive compositions
JP2001170159A (en) * 1999-12-19 2001-06-26 Alcare Co Ltd Contact skin member having buffering capability
US20040015688A1 (en) * 2000-09-05 2004-01-22 Yu Zhang Eugene Zhen Interactive authentication process
SE519451C2 (en) 2000-10-02 2003-03-04 Moelnlycke Health Care Ab Dry skin-friendly glue that affects the skin's pH value
GB0110284D0 (en) 2001-04-26 2001-06-20 Avery Dennison Corp Mouldable hydrocolloid adhesive compositions
RU2276998C2 (en) * 2001-05-01 2006-05-27 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Hydrogel compositions
JP4073231B2 (en) * 2002-03-28 2008-04-09 久光製薬株式会社 Sheet patch
AU2003257615A1 (en) * 2002-08-30 2004-03-19 Hisamitsu Pharmaceutical Co., Inc. Adhesive gel composition for iontophoresis preparation and process for producing the same
DK200300018A (en) 2003-01-10 2004-07-11 Coloplast As ostomy appliance
US6746765B1 (en) 2003-01-23 2004-06-08 Bristol-Myers Squibb Company Hydrocolloid adhesive tape
NZ541543A (en) * 2003-01-28 2008-02-29 Teikoku Seiyaku Kk Thin aqueous cataplasm having a support and a pressure-sensitive adhesive layer
US7031972B2 (en) * 2003-07-21 2006-04-18 Innopath Software, Inc. Algorithms for block-level code alignment of software binary files
US20070009582A1 (en) * 2003-10-07 2007-01-11 Madsen Niels J Composition useful as an adhesive and use of such a composition
WO2005032610A1 (en) * 2003-10-07 2005-04-14 Coloplast A/S An adhesive composition and use of such composition
US20050096611A1 (en) 2003-10-30 2005-05-05 Stoyer Brian C. Multi-adhesive medical appliance
US20050282977A1 (en) 2004-06-17 2005-12-22 Emil Stempel Cross-linked gel and pressure sensitive adhesive blend, and skin-attachable products using the same
KR20080000647A (en) 2005-04-28 2008-01-02 오노 야꾸힝 고교 가부시키가이샤 Transdermal absorption preparation
JP2007034343A (en) * 2005-07-21 2007-02-08 Fujitsu Ltd Genetic information display device, genetic information display method, genetic information display program and recording medium
US20070060855A1 (en) 2005-07-28 2007-03-15 Hollister Incorporated Pressure-sensitive adhesive compositions and self-adhering wound dressings comprising same
AU2006332235A1 (en) 2005-12-30 2007-07-12 Coloplast A/S A layered adhesive construct having a mouldable layer as skin contact surface
DE602007009362D1 (en) 2006-01-18 2010-11-04 Coloplast As ADHESIVE STICKER COMPOSITIONS WITH DIFFERENT HYDROCOLLIDE COMPOSITIONS
WO2007092289A2 (en) 2006-02-02 2007-08-16 H.B. Fuller Licensing & Financing, Inc. Ostomy article including hot melt superabsorbent polymer composition and method of using the same
JP5147207B2 (en) * 2006-09-22 2013-02-20 帝國製薬株式会社 Hydrogel wound dressing
MX2010009302A (en) * 2008-02-25 2010-09-24 Teikoku Seiyaku Kk Wound-covering hydrogel material.
KR101616579B1 (en) * 2008-04-23 2016-04-28 코와 가부시키가이샤 External skin patch
US20110306677A1 (en) 2009-02-20 2011-12-15 Hiroshi Kataoka Pressure Sensitive Adhesive Composition and Pressure Sensitive Adhesive Tape
JP2011012015A (en) * 2009-07-01 2011-01-20 Lion Corp Plaster
JP5544935B2 (en) * 2010-03-05 2014-07-09 ライオン株式会社 Patch
AU2011304133A1 (en) 2010-09-17 2013-03-28 Teikoku Seiyaku Co., Ltd. Method for using hydrogel sheet for treating wound
US8945076B2 (en) 2011-08-03 2015-02-03 Hollister Incorporated Ostomy appliance with integrated belt tabs
CN102552221B (en) 2012-01-11 2013-09-04 中国人民解放军军事医学科学院微生物流行病研究所 Tulobuterol patch and preparation method thereof
AU2013226154B2 (en) * 2012-02-29 2015-07-09 Hollister Incorporated Buffered adhesive compositions for skin-adhering products and methods of making same
US9422463B2 (en) 2012-02-29 2016-08-23 Hollister, Inc. Buffered adhesive compositions for skin-adhering medical products
CN102634296A (en) 2012-04-28 2012-08-15 江苏宝力泰新材料科技有限公司 Self-fusion anti-corrosion adhesive tape and preparation method of self-fusion adhesive thereof
CA2974219A1 (en) 2015-02-02 2016-08-11 Coloplast A/S Ostomy device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750136A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US20050215727A1 (en) * 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
US20040156886A1 (en) * 2001-06-12 2004-08-12 Yasuhisa Kose Sheet-like patch agent
US20070219287A1 (en) * 2006-03-16 2007-09-20 Hollister Incorporated Hydrocolloid-containing adhesive composition having network of fibrillated polymeric fibers
US20130316042A1 (en) * 2010-06-25 2013-11-28 Cadbury Adams Mexico, S. De R.L. De C.V. Enhanced release of lipophilic ingredients from chewing gum with hydrocolloids

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166838B2 (en) 2007-06-12 2021-11-09 Convatec Technologies Inc. Ostomy appliance
US11628093B2 (en) 2008-05-08 2023-04-18 Convatec Technologies, Inc. Wound dressing
US11458044B2 (en) 2008-09-29 2022-10-04 Convatec Technologies Inc. Wound dressing
US11076979B2 (en) 2008-11-19 2021-08-03 Convatec Technologies Inc. Ostomy pouch appliance
US11426485B2 (en) 2009-07-07 2022-08-30 Convatec Technologies Inc. Pressure sensitive adhesives with amphiphilic copolymer
US11076978B2 (en) 2009-09-11 2021-08-03 Convatec Technologies Inc. Controlled discharge ostomy appliance and shield therefor
US11166837B2 (en) 2010-09-30 2021-11-09 Convatec Technologies Inc. Ostomy pouch with filtering system
US11135315B2 (en) 2010-11-30 2021-10-05 Convatec Technologies Inc. Composition for detecting biofilms on viable tissues
US11241525B2 (en) 2010-12-08 2022-02-08 Convatec Technologies Inc. Wound exudate monitor accessory
US11116884B2 (en) 2010-12-08 2021-09-14 Convatec Technologies Inc. Integrated system for assessing wound exudates
US11583430B2 (en) 2011-09-02 2023-02-21 Convatec Ltd. Skin contact material
US11103621B2 (en) 2011-09-02 2021-08-31 Convatec Ltd Discharge solidifier and malodour control
US11241339B2 (en) 2011-11-29 2022-02-08 Convatec Inc. Perforated binder for laminated wound dressing
US10968543B2 (en) 2011-12-01 2021-04-06 Convatec Technologies Inc. Wound dressing for use in vacuum therapy
US11286601B2 (en) 2012-12-20 2022-03-29 Convatec Technologies, Inc. Processing of chemically modified cellulosic fibres
US11890218B2 (en) 2014-04-24 2024-02-06 Convatec Technologies Inc. Ostomy pouch filter system
JP2017530216A (en) * 2014-08-20 2017-10-12 ホリスター・インコーポレイテッドHollister Incorporated Buffer adhesive composition for skin adhesive medical device
US11039950B2 (en) 2015-10-14 2021-06-22 Convatec Technologies Inc. Medical device with an opening system
US11717434B2 (en) 2015-10-14 2023-08-08 Convatec Technologies Inc. Medical device with an opening system
US11723808B2 (en) 2016-03-30 2023-08-15 Convatec Technologies Inc. Detecting microbial infections in wounds
US11740241B2 (en) 2016-03-30 2023-08-29 Synovo Gmbh Construct including an anchor, an enzyme recognition site and an indicator region for detecting microbial infection in wounds
US11278640B2 (en) 2016-05-04 2022-03-22 Coloplast A/S Adhesive wafer with a neutralizer matrix
US11452808B2 (en) 2016-07-08 2022-09-27 Convatec Technologies Inc. Fluid flow sensing
US11266774B2 (en) 2016-07-08 2022-03-08 Convatec Technologies Inc. Fluid collection apparatus
US11596554B2 (en) 2016-07-08 2023-03-07 Convatec Technologies Inc. Flexible negative pressure system
US11491254B2 (en) 2017-11-08 2022-11-08 Coloplast A/S Adhesive wafer with a neutralizer matrix
WO2019091528A1 (en) * 2017-11-08 2019-05-16 Coloplast A/S An adhesive wafer with a neutralizer matrix
US11786631B2 (en) 2017-11-08 2023-10-17 Coloplast A/S Ostomy appliance having a neutralizing layer deposited on adhesive of a wafer and located inside a waste collection bag
US11911310B2 (en) 2017-11-08 2024-02-27 Coloplast A/S Adhesive wafer with a neutralizer matrix
WO2019165751A1 (en) * 2018-02-28 2019-09-06 江苏金太阳纺织科技股份有限公司 Buffering agent for balancing ph value of fabric and preparation method therefor
US11737906B2 (en) 2019-02-07 2023-08-29 Convatec Technologies, Inc. Adjustable convex ostomy device
US11590017B2 (en) 2019-04-25 2023-02-28 Convatec Technologies Inc. Ostomy wafers incorporating adhesives, ostomy devices including the same, and methods of applying ostomy wafers and ostomy devices
US11679020B2 (en) 2019-04-25 2023-06-20 Convatec Technologies, Inc. Perforated chamber ostomy wafers, ostomy devices including the same, and methods of applying ostomy wafers and ostomy devices
US11638658B2 (en) 2019-04-25 2023-05-02 Convatec Technologies, Inc. Ostomy wafers incorporating adhesives and foam layers, ostomy devices including the same, and methods of applying ostomy wafers and ostomy devices
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems

Also Published As

Publication number Publication date
JP2015502430A (en) 2015-01-22
US20210378874A1 (en) 2021-12-09
LT2819627T (en) 2019-12-27
CA2851870A1 (en) 2013-09-06
EP2819627A2 (en) 2015-01-07
AU2013226154A1 (en) 2014-04-17
PL2819627T3 (en) 2020-04-30
EP2819627B1 (en) 2019-11-13
EP2819628A4 (en) 2015-12-09
EP2819628A1 (en) 2015-01-07
ES2768599T3 (en) 2020-06-23
AU2013226156B2 (en) 2015-10-29
WO2013130566A3 (en) 2014-12-11
CA2851870C (en) 2017-03-07
AU2013226156A1 (en) 2014-04-17
US9763833B2 (en) 2017-09-19
US20170340487A1 (en) 2017-11-30
AU2013226154B2 (en) 2015-07-09
JP2015508421A (en) 2015-03-19
US11147716B2 (en) 2021-10-19
JP2017057396A (en) 2017-03-23
CA2851868A1 (en) 2013-09-06
EP3622971A1 (en) 2020-03-18
JP6092243B2 (en) 2017-03-08
US20190380882A1 (en) 2019-12-19
US11819389B2 (en) 2023-11-21
US10434015B2 (en) 2019-10-08
EP2819627A4 (en) 2015-12-09
US20130231600A1 (en) 2013-09-05
HUE047625T2 (en) 2020-05-28
WO2013130564A1 (en) 2013-09-06
WO2013130566A2 (en) 2013-09-06
DK2819627T3 (en) 2020-02-03

Similar Documents

Publication Publication Date Title
US11819389B2 (en) Buffered adhesive compositions for skin-adhering medical products
US11826235B2 (en) Buffered adhesive compositions for skin-adhering medical products
AU2021204405B2 (en) Buffered Adhesive Compositions for Skin-Adhering Medical Products
US9422463B2 (en) Buffered adhesive compositions for skin-adhering medical products
US20240041659A1 (en) Buffered adhesive compositions for skin-adhering medical products

Legal Events

Date Code Title Description
AS Assignment

Owner name: HOLLISTER INCORPORATED, ILLINOIS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAYLOR, MICHAEL GERARD;MURAHATA, RICHARD IWAO;REEL/FRAME:030083/0294

Effective date: 20130308

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION